Citations

Clear

4610 citation(s) found for "Lu, Brian".

Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
Baker, Mark E. , Bemelman, Willem A. , D’Haens, Geert , D’Hoore, A., Feakins, Roger , Fleshner, Phillip , Ha, Christina , Lyu, R., Mao, Ren , Sandborn, William J. , Ng, S, Silverberg, Mark S. , Bruining, David H. , Feagan, Brian G. , Bettenworth, Dominik , Fletcher, Joel G. , Jairath, Vipul , Lu, Cathy , Dignass, Axel , Dotan, Iris , Henderson, G., Panés, Julián , Rogler, Gerhard , Rimola, Jordi , Siegmund, Britta , Taylor, Stuart A. , Verstockt, Bram , Gordon, Ilyssa O. , Rieder, F.

Mayo Clinic

Zeitschrift für Gastroenterologie | October 26, 2023 | Volume: 61 | Issue: 08 | Pages: e421-e422

10.1055/s-0043-1771750 Get It

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab
Ramsower, Colleen , Robetorye, Ryan S. , Mwangi, Raphael , Maurer, Matthew J. , Villa, Diego , McDonnell, Tim, Cohen, Jonathon B. , Clot, Guillem , Bühler, Marco M. , Kulis, Marta , Giné, Eva , Cook, James R. , Hill, Brian T. , Beiske, Klaus , Reichart, Alexander, Hartmann, Sylvia , Rimsza, Lisa M. , Ramsower, Colleen A , Maurer, Matthew , Villa, Diego , Feldman, Andrew, Cohen, Jonathon B , Martin-Subero, Jose Ignacio , Cook, James R , Hill, Brian , Raess, Philipp W , Hartmann, Sylvia , Holte, Harald , Rimsza, Lisa M , Rosenthal, Allison , McDonnell, Tim, Feldman, Andrew L. , Habermann, Thomas M. , Campo, Elı́as , Raess, Philipp W. , Holte, Harald , Scott, David W.

Mayo Clinic

British Journal of Haematology | October 26, 2023 | Volume: 204 | Issue: 1 | Pages: 160-170

10.1111/bjh.19153 | PMID 37881141 Get It

SummaryMantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high‐risk call by a simplified MCL international prognostic index (s‐MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high‐risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s‐MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk‐stratify older MCL patients in future clinical trials.
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson, James N. , Villa, Diego , Chapani, Parv , Li, Shaoying , Medeiros, L. Jeffrey , Wang, Michael , Cohen, Jonathon B. , Churnetski, Michael C. , Hill, Brian T. , Hernandez‐Ilizaliturri, Francisco J. , Kothari, Shalin , Bast, Martin, Fenske, Timothy S. , Gari, Swapna Narayana Rao, Maddocks, Kami J. , Bachanová, Veronika , Kolla, Bhaskar , Donovan, Alexandra M., Wagner‐Johnston, Nina D. , Messmer, Marcus , Anderson, Jennifer K., Reddy, Nishitha , Glenn, Martha, Inwards, David J. , Ristow, Kay M., Rajguru, Saurabh, Evens, Andrew M. , Klein, Andreas K. , Umyarova, Elvira , Pulluri, Bhargavi , Amengual, Jennifer E. , Diefenbach, Catherine , Fisher, Richard I., Villa, Diego , Gerrie, Alina S , Chapani, Parv , Li, Shaoying , Medeiros, L Jeffrey , Wang, Michael L , Sawalha, Yazeed , Vose, Julie , Bond, David A , Kolla, Bhaskar , Lansigan, Frederick , Wagner-Johnston, Nina , Messmer, Marcus , Mehta, Amitkumar , Ristow, Kay, Karmali, Reem , Caimi, Paolo F , Evens, Andrew M , Amengual, Jennifer E , Bachanova, Veronika , Diefenbach, Catherine S , Handorf, Elizabeth A. , Gerrie, Alina S. , Sawalha, Yazeed , Vose, Julie M. , Bond, David A. , Chavez, Julio C , Shah, Bijal , Lansigan, Frederick , Burns, Timothy Francis , Mehta, Amitkumar , Kovach, Alexandra E. , Landsburg, Daniel J. , Karmali, Reem , Kaplan, Jason , Caimi, Paolo F. , Lue, Jennifer Kimberly , Barta, Stefan K

Mayo Clinic

Blood Advances | October 24, 2023 | Volume: 7 | Issue: 24 | Pages: 7393-7401

10.1182/bloodadvances.2023010757 | PMID 37874912 Get It

Abstract Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis
Dornhoffer, James R. , Plitt, Aaron , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Saoji, Aniket A. , Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 45 | Issue: 1 | Pages: 29-35

10.1097/mao.0000000000004047 | PMID 37875011 Get It

Objective To compare cochlear implant (CI) and auditory brainstem implant (ABI) performance in patients with NF2-related schwannomatosis (NF2) Study Design Historical cohort. Setting Tertiary academic center. Patients A total of 58 devices among 48 patients were studied, including 27 ABIs implanted from 1997 to 2022 and 31 CIs implanted from 2003 to 2022. Three patients had bilateral ABIs, three had bilateral CIs, three had an ABI on one side and a CI on the other, one had a CI that was later replaced with an ipsilateral ABI, and one had an ABI and CI concurrently on the same side. Interventions CI or ABI ipsilateral to vestibular schwannoma. Main Outcome Measures Open-set speech perception, consonant-nucleus-consonant word scores, and AzBio sentence in quiet scores. Results Among all patients, 27 (47%) achieved open-set speech perception, with 35 (61%) daily users at a median of 24 months (interquartile range [IQR], 12–87 mo) after implantation. Comparing outcomes, CIs significantly outperformed ABIs; 24 (77%) CIs achieved open-set speech perception compared with 3 (12%) ABIs, with median consonant-nucleus-consonant and AzBio scores of 31% (IQR, 0–52%) and 57% (IQR, 5–83%), respectively, for CIs, compared with 0% (IQR, 0–0%) and 0% (IQR, 0–0%), respectively, for ABIs. Patients with ABIs were younger at diagnosis and at implantation, had larger tumors, and were more likely to have postoperative facial paresis. Conclusion Many patients with NF2-associated vestibular schwannoma achieved auditory benefit with either a CI or an ABI; however, outcomes were significantly better in those patients who were able to receive a CI. When disease and anatomy permit, hearing rehabilitation with a CI should be considered over an ABI in these patients. Tumor management strategies that increase the ability to successfully use CIs should be strongly considered given the high risk of losing bilateral functional acoustic hearing in this population.
Rationale for the Development of a Novel Clinical Grading Scale for Postoperative Facial Nerve Function: Results of a Multidisciplinary International Working Group
Carlson, Matthew L. , Lohse, Christine M. , Babu, Seilesh C. , Barker, Frederick G., Barnett, Samuel , Biggs, Nigel, Boahene, Kofi , Breen, Joseph T. , Brown, Kevin D. , Cayé‐Thomasen, Per , Cosetti, Maura K. , Deep, Nicholas L. , Dornhoffer, James R. , Forner, David , Hansen, Marlan R. , Kalamarides, Michel , Kim, Irene A., Kircher, Matthew L., Link, Michael J., Lloyd, Simon , Lund‐Johansen, Morten , Marinelli, John P. , Matthies, Cordula , Moore, Eric J. , Nassiri, Ashley M. , Neff, Brian A., Patel, Neil S. , Celda, María Peris, Plitt, Aaron , Sweeney, Alex D. , Tasche, Kendall K. , Tatagiba, Marcos , Tveiten, Øystein Vesterli , Vrabec, Jeffrey T. , Wanna, George B. , Weisskopf, Peter A., Tatagiba, Marcos , Agazzi, Siviero , Bi, Wenya Linda , Dey, Jacob K. , Gurgel, Richard Klaus , Hunter, Jacob B. , King, Andrew Thomas , Lassaletta, Luis , Mehta, Vikas , Nelson, Rick F , Olson, Jeffrey J. , Price, Daniel L. , Roland, J. Thomas , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | October 24, 2023 | Volume: 44 | Issue: 10 | Pages: e747-e754

10.1097/mao.0000000000004039 | PMID 37875014 Get It

Objective The objective of the current study was to present the results of an international working group survey identifying perceived limitations of existing facial nerve grading scales to inform the development of a novel grading scale for assessing early postoperative facial paralysis that incorporates regional scoring and is anchored in recovery prognosis and risk of associated complications. Study Design Survey. Setting A working group of 48 multidisciplinary clinicians with expertise in skull base, cerebellopontine angle, temporal bone, or parotid gland surgery. Results House-Brackmann grade is the most widely used system to assess facial nerve function among working group members (81%), although more than half (54%) agreed that the system they currently use does not adequately estimate the risk of associated complications, such as corneal injury, and confidence in interrater and intrarater reliability is generally low. Simplicity was ranked as the most important attribute of a novel postoperative facial nerve grading system to increase the likelihood of adoption, followed by reliability and accuracy. There was widespread consensus (91%) that the eye is the most critical facial region to focus on in the early postoperative setting. Conclusions Members were invited to submit proposed grading systems in alignment with the objectives of the working group for subsequent validation. From these data, we plan to develop a simple, clinically anchored, and reproducible staging system with regional scoring for assessing early postoperative facial nerve function after surgery of the skull base, cerebellopontine angle, temporal bone, or parotid gland.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML
Huang, Ying , Lance, Jennie Rachel, Mao, Hsiaoyin, Dunbar, Andrew , McNulty, Samantha N. , Baer, Maria R. , Kovacsovics, Tibor , Blum, William , Schiller, Gary J. , Olin, Rebecca L. , Foran, James M. , Litzow, Mark R. , Patel, Prapti A. , Boyiadzis, Michael , Collins, Robert H. , Chervin, Jordan , Vergilio, Jo‐Anne, Heerema, Nyla A. , Rosenberg, Leonard, Chen, Timothy L. , Yocum, Ashley O. , Druggan, Franchesca , Marcus, Sonja, Stefanos, Mona , Borate, Uma , Burd, Amy , Byrd, John C. , Stein, Eytan M. , Huang, Ying , Cai, Sheng F , Litzow, Mark R. , Lin, Tara L , Druker, Brian J , Mims, Alice S , Byrd, John C , Druley, Todd E. , Li, Yan , Stock, Wendy , Lin, Tara L. , Foster, Matthew C , Shoben, Abigail B. , Levine, Ross L.

Mayo Clinic

Blood Advances | October 23, 2023 | Volume: 8 | Issue: 2 | Pages: 429-440

10.1182/bloodadvances.2023010563 | PMID 37871309 Get It

Abstract Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy, we applied a risk-adapted approach to assess the efficacy of ENA monotherapy for patients aged ≥60 years with newly diagnosed IDH2-mutant AML in whom genomic profiling demonstrated that mutant IDH2 was in the dominant leukemic clone. Patients for whom ENA monotherapy did not induce a complete remission (CR) or CR with incomplete blood count recovery (CRi) enrolled in a phase 1b cohort with the addition of azacitidine. The phase 2 portion assessing the overall response to ENA alone demonstrated efficacy, with a composite complete response (cCR) rate (CR/CRi) of 46% in 60 evaluable patients. Seventeen patients subsequently transitioned to phase 1b combination therapy, with a cCR rate of 41% and 1 dose-limiting toxicity. Correlative studies highlight mechanisms of clonal elimination with differentiation therapy as well as therapeutic resistance. This study demonstrates both efficacy of ENA monotherapy in the upfront setting and feasibility and applicability of a risk-adapted approach to the upfront treatment of IDH2-mutant AML. This trial is registered at www.clinicaltrials.gov as #NCT03013998.
T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease
Brier, Matthew R. , Gordon, Brian A. , Flores, Shaney , Keefe, Sarah , Hornbeck, Russ C. , Ances, Beau M. , Xiong, Chengjie , Wang, Guoqiao , Raji, Cyrus A. , Libre‐Guerra, Jorge J., Perrin, Richard J. , Daniels, Alisha , Day, Gregory S. , Fulham, Michael , Jack, Clifford R. , Fougère, Christian la , Oh, Hwamee , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , (DIAN), For the Dominantly Inherited Alzheimer Network, Rahmani, Farzaneh , Cash, David M , Jack, Clifford R , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Ances, Beau M , Morris, John C , McKay, Nicole S. , Joseph‐Mathurin, Nelly , Xiong, Chengjie , McDade, Eric , Karch, Celeste M. , Brickman, Adam M. , Reischl, Gerald , Schofield, Peter R. , Cash, David M. , Ikeuchi, Takeshi , Klunk, William E. , Bateman, Randall J. , Benzinger, Tammie L.S. , (DIAN), For the Dominantly Inherited Alzheimer Network

Mayo Clinic

Human Brain Mapping | October 23, 2023 | Volume: 44 | Issue: 18 | Pages: 6375-6387

10.1002/hbm.26514 | PMID 37867465 Get It

AbstractCarriers of mutations responsible for dominantly inherited Alzheimer disease provide a unique opportunity to study potential imaging biomarkers. Biomarkers based on routinely acquired clinical MR images, could supplement the extant invasive or logistically challenging) biomarker studies. We used 1104 longitudinal MR, 324 amyloid beta, and 87 tau positron emission tomography imaging sessions from 525 participants enrolled in the Dominantly Inherited Alzheimer Network Observational Study to extract novel imaging metrics representing the mean (μ) and standard deviation (σ) of standardized image intensities of T1‐weighted and Fluid attenuated inversion recovery (FLAIR) MR scans. There was an exponential decrease in FLAIR‐μ in mutation carriers and an increase in FLAIR and T1 signal heterogeneity (T1‐σ and FLAIR‐σ) as participants approached the symptom onset in both supramarginal, the right postcentral and right superior temporal gyri as well as both caudate nuclei, putamina, thalami, and amygdalae. After controlling for the effect of regional atrophy, FLAIR‐μ decreased and T1‐σ and FLAIR‐σ increased with increasing amyloid beta and tau deposition in numerous cortical regions. In symptomatic mutation carriers and independent of the effect of regional atrophy, tau pathology demonstrated a stronger relationship with image intensity metrics, compared with amyloid pathology. We propose novel MR imaging intensity‐based metrics using standard clinical T1 and FLAIR images which strongly associates with the progression of pathology in dominantly inherited Alzheimer disease. We suggest that tau pathology may be a key driver of the observed changes in this cohort of patients.
Incidence and Outcomes of Bloodstream Infection After Arterial Aneurysm Repair: Findings From a Population-Based Study
Tabaja, Hussam , Chesdachai, Supavit , Lahr, Brian D. , Chesdachai, Supavit , Tabaja, Hussam , Baddour, Larry M. , DeMartino, Randall R. , DeSimone, Daniel C.

Mayo Clinic

Open Forum Infectious Diseases | October 21, 2023 | Volume: 10 | Issue: 11 | Pages: No page available

10.1093/ofid/ofad521 | PMID 38023557 Get It

Abstract Background Limited research has focused on bloodstream infection (BSI) in patients with arterial grafts. This study aims to describe the incidence and outcomes of BSI after arterial aneurysm repair in a population-based cohort. Methods The expanded Rochester Epidemiology Project (e-REP) was used to analyze aneurysm repairs in adults (aged ≥18 years) residing in 8 counties in southern Minnesota from January 2010 to December 2020. Electronic records were reviewed for the first episode of BSI following aneurysm repair. BSI patients were assessed for vascular graft infection (VGI) and followed for all-cause mortality. Results During the study, 643 patients had 706 aneurysm repairs: 416 endovascular repairs (EVARs) and 290 open surgical repairs (OSRs). Forty-two patients developed BSI during follow-up. The 5-year cumulative incidence of BSI was 4.7% (95% confidence interval [CI], 3.0%–6.4%), with rates of 4.0% (95% CI, 1.8%–6.2%) in the EVAR group and 5.8% (95% CI, 2.9%–8.6%) in the OSR group (P = .052). Thirty-nine (92.9%) BSI cases were monomicrobial, 33 of which were evaluated for VGI. VGI was diagnosed in 30.3% (10/33), accounting for 50.0% (8/16) of gram-positive BSI cases compared to 11.8% (2/17) of gram-negative BSI cases (P = .017). The 1-, 3-, and 5-year cumulative post-BSI all-cause mortality rates were 22.2% (95% CI, 8.3%–34.0%), 55.8% (95% CI, 32.1%–71.2%), and 76.8% (95% CI, 44.3%–90.3%), respectively. Conclusions The incidence of BSI following aneurysm repair was overall low. VGI was more common with gram-positive compared to gram-negative BSI. All-cause mortality following BSI was high, which may be attributed to advanced age and significant comorbidities in our cohort.
Stent-assisted Woven EndoBridge device for the treatment of intracranial aneurysms: an international multicenter study
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Regenhardt, Robert W. , Guenego, Adrien , Lay, Sovann V. , Balushi, Ali Al , Premat, Kévin , Namaani, Kareem El, Möhlenbruch, Markus , Foreman, Paul M. , Vachhani, Jay A. , Župančić, Vedran , Rai, Hamid, Tutino, Vincent M. , Mirshahi, Shervin , Ghozy, Sherief , Rabinov, James D. , Ren, Yifan , Goren, Oded , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M. , Nguyên, Anh , Jones, Jesse , Psychogios, Marios, Spears, Julian , Marotta, Thomas R. , Bres-Bullrich, Maria , Mayich, Michael , Salem, Mohamed M. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Ulfert, Christian , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Asadi, Hamed , Ducruet, Andrew F. , Albuquerque, Felipe C , Patel, Nirav J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Stapleton, Christopher J. , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Patel, Aman B. , Tawk, Rabih, Ghozy, Sherief , Diestro, Jose Danilo B , Shotar, Eimad , Tutino, Vincent M , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Dibas, Mahmoud , Vranic, Justin E. , Renieri, Leonardo , Shotar, Eimad , Saliou, Guillaume , Lylyk, Iván , Hafeez, Muhammad Ubaid , Rutledge, Caleb , Harker, Pablo , Alotaibi, Naif M. , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Salehani, Arsalaan , Psychogios, Marios‐Nikos , Mendes Pereira, Vitor , Parra-Fariñas, Carmen , Bullrich, María Bres , Domingo, Ricardo A. , Huynh, Thien , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Jabbour, Pascal , Limbucci, Nicola , Aziz‐Sultan, Mohammad Ali , Cuellar, Hugo , Cognard, Christophe , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | October 21, 2023 | Volume: 140 | Issue: 4 | Pages: 1071-1079

10.3171/2023.8.jns235 | PMID 37862717 Get It

OBJECTIVE The Woven EndoBridge (WEB) device is an intrasaccular flow disruptor designed for wide-necked bifurcation aneurysms. These aneurysms may require the use of a concomitant stent. The objective of this study was to determine the clinical and radiological outcomes of patients undergoing stent-assisted WEB treatment. In addition, the authors also sought to determine the predictors of a concomitant stent in aneurysms treated with the WEB device. METHODS The data for this study were taken from the WorldWideWEB Consortium, an international multicenter cohort including patients treated with the WEB device. Aneurysms were classified into two groups based on treatment: stent-assisted WEB and WEB device alone. The authors compared clinical and radiological outcomes of both groups. Univariable and multivariable binary logistic regression analyses were performed to determine factors that predispose to stent use. RESULTS The study included 691 intracranial aneurysms (31 with stents and 660 without stents) treated with the WEB device. The adequate occlusion status did not differ between the two groups at the latest follow-up (83.3% vs 85.6%, p = 0.915). Patients who underwent stenting had more thromboembolic (32.3% vs 6.5%, p < 0.001) and procedural (16.1% vs 3.0%, p < 0.001) complications. Aneurysms treated with a concomitant stent had wider necks, greater heights, and lower dome-to-neck ratios. Increasing neck size was the only significant predictor for stent use. CONCLUSIONS This study demonstrates that there is no difference in the degree of aneurysm occlusion between the two groups; however, complications were more frequent in the stent group. In addition, a wider aneurysm neck predisposes to stent assistance in WEB-treated aneurysms.